Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Pfizer
ClinicalTrials.gov Identifier:
NCT01364571
First received: May 31, 2011
Last updated: July 25, 2014
Last verified: July 2014

May 31, 2011
July 25, 2014
August 2011
April 2012   (final data collection date for primary outcome measure)
  • Number and proportion of subjects reporting local reactions (size of redness and/or swelling and severity of pain at the injection site) and severity of the local reactions as self-reported on electronic diaries (e-diaries) [ Time Frame: 14 days ] [ Designated as safety issue: Yes ]
  • Number and proportion of subjects reporting solicited systemic events (fever, vomiting, diarrhea, headache, fatigue, new or worsening muscle pain, new or worsening joint pain) and severity of solicited systemic events self-reported on electronic diaries [ Time Frame: 14 days ] [ Designated as safety issue: Yes ]
  • Number and proportion of subjects reporting unsolicited AEs and serious adverse events (SAEs) categorized according to the Medical Dictionary for Regulatory Activities (MedDRA) [ Time Frame: 1 month (AEs), 6 months (SAEs) ] [ Designated as safety issue: Yes ]
  • Number and proportion of Phase 1 subjects with abnormal hematology, coagulation and blood chemistry lab assessments; number and proportion of Phase 1 subjects with grading shifts in hematology, coagulation and blood chemistry laboratory assessments. [ Time Frame: 14 days ] [ Designated as safety issue: Yes ]
  • Proportion of subjects achieving antibody responses to specific antigens with results greater than or equal to thresholds specific to each of the 4 antigens in the vaccine based on immunoglobulin-binding and/or opsonophagocytic activity assays. [ Time Frame: 1 month ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT01364571 on ClinicalTrials.gov Archive Site
  • Immunoglobulin concentrations for each antigen at each applicable blood sampling time point, [ Time Frame: various, up to 12 months ] [ Designated as safety issue: No ]
  • Opsonophagocytic activity (OPA) titers at each applicable blood sampling time point, [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Immunoglobulin geometric mean fold rise (GMFR) for each antigen [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Geometric mean fold rise on opsonophagocytic activity assay titers [ Time Frame: 1 month ] [ Designated as safety issue: No ]
  • Proportion of subjects achieving antibody responses to specific antigens with results greater than or equal to thresholds specific to each of the 4 antigens in the vaccine at at each applicable visit [ Time Frame: various, up to 12 months ] [ Designated as safety issue: No ]
  • Immunoglobulin concentration for each antigen at each applicable blood sampling time point, [ Time Frame: various, up to 12 months ] [ Designated as safety issue: No ]
  • Opsonophagocytic activity (OPA) titers for 2 of the antigens at each applicable blood sampling time point, [ Time Frame: 1 month ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
Evaluation of a Single Vaccination With One of Three Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years
Phase I/2 Placebo-Controlled, Randomized, Double-Blind Trial to Evaluate the Safety, Tolerability, and Immunogenicity of 3 Ascending Dose Levels of a 4-Antigen Staphylococcus Aureus Vaccine (SA4Ag) in Healthy Adults Aged 18 to <65 Years

This is a first-in-human (Phase 1) and Phase 2 study of a single vaccination with one of three dose levels of an investigational vaccine against Staphylococcus aureus (SA4Ag). The main goal of the study is to determine how safe and well tolerated the vaccine is as well as to describe the immune response elicited by the vaccine in healthy adults aged 18 to <65 years. In addition, the study aims to assess the effect of the SA4Ag vaccine on the presence of the Staphylococcus aureus on the skin and within the nose, throat and perineum of healthy adults aged 18 to <65 years.

Not Provided
Interventional
Phase 1
Phase 2
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Staphylococcal Infections
  • Biological: SA4Ag vaccine low dose
    Subjects receive 1 intramuscular injection (0.5 mL) of the low dose level of the SA4Ag vaccine.
  • Procedure: Blood draw
    Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
  • Procedure: Colonization swab sample
    Colonization swabs will be collected from all subjects at various time points throughout the study.
  • Biological: SA4Ag vaccine mid dose
    Subjects receive 1 intramuscular injection (0.5 mL) of the mid dose level of the SA4Ag vaccine.
  • Procedure: Blood sample
    Blood for hematology, coagulation and blood chemistry will be collected at a minimum of 3 timepoints from Phase 1 subjects. Blood for immunogenicity will be collected from all subjects at various timepoints.
  • Biological: SA4Ag vaccine high dose
    Subjects receive 1 intramuscular injection (0.5 mL) of the high dose level of the SA4Ag vaccine.
  • Biological: Placebo
    Subjects receive one intramuscular injection (0.5 mL) of commercially available normal saline.
  • Experimental: 1
    SA4Ag vaccine low dose
    Interventions:
    • Biological: SA4Ag vaccine low dose
    • Procedure: Blood draw
    • Procedure: Colonization swab sample
  • Experimental: 2
    SA4Ag vaccine mid dose
    Interventions:
    • Biological: SA4Ag vaccine mid dose
    • Procedure: Blood sample
    • Procedure: Colonization swab sample
  • Experimental: 3
    SA4Ag vaccine high dose
    Interventions:
    • Biological: SA4Ag vaccine high dose
    • Procedure: Blood draw
    • Procedure: Colonization swab sample
  • Placebo Comparator: 4
    Placebo
    Interventions:
    • Biological: Placebo
    • Procedure: Blood draw
    • Procedure: Colonization swab sample
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
456
January 2013
April 2012   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy adults aged 18 to <65 years at enrollment, as determined by medical history, physical examination, and the clinical judgment of the investigator to be eligible for the study. Subjects with preexisting chronic medical conditions determined to be stable may be included.
  • Availability for the entire duration of the study, and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures including completion of the electronic diary (e-diary) from Day 1 to Day 14 following vaccination(s).
  • Ability to be contacted by telephone during study participation.
  • All male and female subjects who are biologically capable of having children must agree and commit to the use of a reliable method of birth control for the duration of the study.

Exclusion Criteria:

  • Unstable chronic medical condition or disease requiring significant change in therapy or hospitalization within 3 months before receipt of study vaccine.
  • Serious chronic medical disorders and any other disorder that in the investigator's opinion precludes the subject from participating in the study
  • Donation of blood volume of 250 mL or greater (excluding protocol-required blood collection), or donation of plasma within 3 months prior to enrollment.
  • Bleeding condition associated with prolonged bleeding time that may contraindicate intramuscular injection or blood draw including subjects taking anticoagulant, antiplatelet and/or antithrombotic agents except for low-dose daily aspirin within 30 days before enrollment through 1 month post-vaccination.
  • Any contraindication to vaccination or vaccine components.
  • Immunocompromised persons and subjects currently on immunosuppressive therapy or with a history of immunosuppressive therapy, including chemotherapy agents or long term systemic corticosteroids.
  • Previous administration of S. aureus vaccination.
  • Any infection proven or suspected to be caused by S. aureus within 6 months preceding study vaccination.
  • Receipt of blood products or immunoglobulins (including monoclonal antibodies) within 12 months before enrollment through conclusion of the study.
  • Participation in other investigational or interventional studies within 30 days before the current study begins and/or during study participation.
  • Subjects who are investigational site staff members or subjects who are immediate family members (1st degree relatives) of investigational site staff members or Pfizer employees directly involved in the conduct of the trial.
  • Residence in a nursing home or long-term care facility or requirement for semiskilled nursing care.
  • For Phase 1 subjects only, any abnormality in screening hematology, coagulation and/or blood chemistry laboratory values.
  • Women who are pregnant (as determined by urine pregnancy test) or breastfeeding.
  • Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the subject inappropriate for entry into this study.
Both
18 Years to 64 Years
Yes
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01364571
B3451001, 6123K1-1005
Yes
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
July 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP